JFG
TGTX icon

Jefferies Financial Group’s TG Therapeutics TGTX Stock Holding History

Jefferies Financial Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-39,000
Closed -$461K – 1983
2022
Q4 		$461K Buy
+39,000
New +$283K ﹤0.01% 1090

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Jefferies Financial Group's TGTX Position: Q1 2026 in Review

Jefferies Financial Group sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 16,000 shares — an estimated $477K sold.

Jefferies Financial Group first reported a position in TGTX in Q1 2023 and held it in 2 quarters. The position peaked at $76.7M in Q1 2023. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Jefferies Financial Group reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 16,000 TG Therapeutics shares in Q1 2026, an estimated $477K.
  • Jefferies Financial Group first reported a position in TG Therapeutics in Q1 2023 and held it in 2 quarters.
  • Jefferies Financial Group's TG Therapeutics position peaked at $76.7M in Q1 2023.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.